btg plc (BTG:London)
btg plc (BTG) Snapshot
|
Open
343.00 GBp
|
Previous Close
339.50 GBp
|
|
|
Day High
358.60 GBp
|
Day Low
341.10 GBp
|
|
|
52 Week High
07/4/12 - 426.00 GBp
|
52 Week Low
08/29/12 - 297.00 GBp
|
|
|
Market Cap
1.2B
|
Average Volume 10 Days
1.2M
|
|
|
EPS TTM
0.05 GBp
|
Shares Outstanding
328.3M
|
|
|
EX-Date
06/7/00
|
P/E TM
70.5x
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
btg plc (BTG) Related Businessweek News
No Related Businessweek News Foundbtg plc (BTG) Details
BTG plc, a specialist healthcare company, engages in developing and commercializing products targeting critical care, cancer, and other disorders. The company markets and sells specialty pharmaceuticals, including CroFab, a snake bite antivenom to treat envenomation from North American pit viper snakes; DigiFab, an antidote to treat patients with life-threatening toxicity resulting from treatment with digoxin; and Voraxaze for the treatment of life-threatening toxicity due to renal impairment resulting from treatment with high-dose methotrexate. It also offers a range of interventional oncology products comprising Bead Block, LC Bead, and DC Bead used to treat patients with hypervascularised tumours and arteriovenous malformations; and brachytherapy products, primarily implantable seeds used to deliver low-dose radiation to localised prostate tumours. The company’s products in development stage include Varisolve (PEM), a Phase III non-surgical product for the treatment of varicose veins; PARAGON Bead that is in Phase II clinical trial to treat metastatic colorectal cancer; and PRECISION Bead, a Phase II clinical trial product for the treatment of primary liver cancer. Its development products also comprise Alemtuzumab, a Phase III clinical trial product used in the treatment of relapsingremitting multiple sclerosis; Abiraterone acetate, a Phase II clinical product for the treatment of advanced prostate cancer; and AZD9773, a Phase IIb clinical stage product used in treating severe sepsis and/or septic shock. The company’s partnered products include Campath, an anti-lymphocyte antibody for the treatment of B-cell chronic lymphocytic leukaemia; MRC Humanisation IP, an antibody humanisation technology for various indications; two-part hip cup, a prosthetic hip joint replacement to avoid dislocation; and Zytiga for the treatment of men with metastatic castration-resistant prostate cancer. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.
btg plc (BTG) Top Compensated Officers
btg plc (BTG) Key Developments
To propose placing of new ordinary shares; to discuss two acquisitions of complementary, high growth, profitable, interventional medicine businesses
BTG plc reported consolidated earnings results for the full year ended March 31, 2013. For the year, the company reported revenue of £233.7 million compared to £197 million a year ago. The company said it delivered overall 19% year-on-year growth and a robust performance in recurring revenue streams. Operating profit was £25.7 million compared to £19.9 million a year ago. Profit before tax was £24.1 million compared to £23 million a year ago. Profit was £16.4 million or 5.0 pence per diluted share compared to £14.6 million or 4.4 pence per diluted share a year ago. Net cash inflow from operating activities was of £55.5 million compared to £47.2 million a year ago. Purchases of intangible assets were of £2.6 million compared to £6 million a year ago. Purchases of property, plant and equipment were of £7.6 million compared to £3.7 million a year ago. The provided revenue guidance for fiscal 2014. The company expects revenue between £235 million and £245 million, which reflects around a 14% year-on-year growth in recurring revenues.
BTG plc, 2013 Earnings Call, May 20, 2013
| Recently Viewed | |||
| BTG:LN | 353.70 GBp | +14.20 |  |
| Company | Last | Change |
| Acacia Research Corp | $23.53 USD | +0.01 |
| EGIS Pharmaceuticals PLC | 20,040 | +70.00 |
| Impax Laboratories Inc | $18.80 USD | +0.20 |
| IP Group PLC | 135.00 GBp | -1.60 |
| Merit Medical Systems Inc | $9.96 USD | -0.01 |
| View Industry Companies | ||
Industry Analysis
BTG
Industry Average
| Valuation | BTG | Industry Range |
| Price/Earnings | 71.0x |
|
| Price/Sales | 4.9x |
|
| Price/Book | 2.7x |
|
| Price/Cash Flow | 37.5x |
|
| TEV/Sales | 4.9x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact BTG PLC, please visit www.btgplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
